Literature DB >> 15224785

Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris.

Daniel J Sheehan1, Jack L Lesher.   

Abstract

A 43-year-old black man with pemphigus vulgaris was started on intravenous immunoglobulin (IVIg) therapy after his disease was found to be refractorry to prednisone alone and prednisone in combination with mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, and oral cyclophosphamide. The patient subsequently developed a deep venous thrombosis (DVT) that was attributed to the IVIg. IVIg has been associated with numerous thrombotic complications such as pulmonary embolism and myocardial infarction. Traditional risk factors for thrombotic complications, such as hypertension, a history of coronary artery disease, and immobility, should be considered as relative contraindications to IVIg therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15224785

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  4 in total

Review 1.  Intravenous immunoglobulin: adverse effects and safe administration.

Authors:  Hedi Orbach; Uriel Katz; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

3.  Recurrent venous thrombosis in an adequately anticoagulated patient with pemphigus vulgaris.

Authors:  Paul R J Ames; Maria Graf; Fabrizio Gentile
Journal:  Thromb J       Date:  2016-03-04

Review 4.  Emerging treatment options for the management of pemphigus vulgaris.

Authors:  Khalaf Kridin
Journal:  Ther Clin Risk Manag       Date:  2018-04-27       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.